secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0000899923-25-000002
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11
--------------------------------------------------------------------------------

- Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.
- Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.
- Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.
- FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.
- FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/0000899923-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/mygn-20250115.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer